Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
Hui
H
Yang
Zhihong
Z
Fang
Yue
Y
Wei
Yumin
Y
Hu
George A
GA
Calin
Hagop M
HM
Kantarjian
Guillermo
G
Garcia-Manero
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage; D015331:Cohort Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000188:drug therapy*; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D035683:MicroRNAs / Q000097:blood*; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy; D016896:Treatment Outcome; D014212:Tretinoin; D014635:Valproic Acid / Q000008:administration & dosage
D000970:Antineoplastic Agents; C532045:MIRN29a microRNA, human; D035683:MicroRNAs; D014212:Tretinoin; D014635:Valproic Acid; D001374:Azacitidine
Blood. 2008 Mar 15;111(6):3183-9
18187662
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
20368434
Leukemia. 2008 Jun;22(6):1095-105
18323801
Blood. 2007 Oct 1;110(7):2302-8
17596541
Blood. 2009 Jun 18;113(25):6411-8
19211935
Blood. 2006 Nov 15;108(10):3271-9
16882711